180 related articles for article (PubMed ID: 22967017)
1. Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors.
Erickson-Miller CL; Pillarisetti K; Kirchner J; Figueroa DJ; Ottesen L; Martin AM; Liu Y; Kamel YM; Messam C
BMC Cancer; 2012 Sep; 12():405. PubMed ID: 22967017
[TBL] [Abstract][Full Text] [Related]
2. CALR mutant protein rescues the response of MPL p.R464G variant associated with CAMT to eltrombopag.
Basso-Valentina F; Levy G; Varghese LN; Oufadem M; Neven B; Boussard C; Balayn N; Marty C; Vainchenker W; Plo I; Ballerini P; Constantinescu SN; Favier R; Raslova H
Blood; 2021 Aug; 138(6):480-485. PubMed ID: 34010413
[TBL] [Abstract][Full Text] [Related]
3. Thrombopoietin receptor levels in tumor cell lines and primary tumors.
Erickson-Miller CL; Chadderton A; Gibbard A; Kirchner J; Pillarisetti K; Baker K; Pandite L; El-Hariry I; Mostafa Kamel Y; Liu Y; Martin AM; Messam C
J Oncol; 2010; 2010():135354. PubMed ID: 21318160
[TBL] [Abstract][Full Text] [Related]
4. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function.
Erhardt JA; Erickson-Miller CL; Aivado M; Abboud M; Pillarisetti K; Toomey JR
Exp Hematol; 2009 Sep; 37(9):1030-7. PubMed ID: 19631713
[TBL] [Abstract][Full Text] [Related]
5. The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma.
Jeong JY; Levine MS; Abayasekara N; Berliner N; Laubach J; Vanasse GJ
J Hematol Oncol; 2015 Apr; 8():37. PubMed ID: 25886818
[TBL] [Abstract][Full Text] [Related]
6. Expression of thrombopoietin and thrombopoietin receptor MPL in human leukemia-lymphoma and solid tumor cell lines.
Graf G; Dehmel U; Drexler HG
Leuk Res; 1996 Oct; 20(10):831-8. PubMed ID: 8960108
[TBL] [Abstract][Full Text] [Related]
7. Humanized VB22B minibody for human Mpl stimulates human megakaryopoiesis but does not enhance platelet aggregation.
Matsuki E; Miyakawa Y; Yamane A; Okamoto S
Exp Hematol; 2011 Aug; 39(8):829-36. PubMed ID: 21605620
[TBL] [Abstract][Full Text] [Related]
8. Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia.
Mitchell WB; Pinheiro MP; Boulad N; Kaplan D; Edison MN; Psaila B; Karpoff M; White MJ; Josefsson EC; Kile BT; Bussel JB
Am J Hematol; 2014 Dec; 89(12):E228-34. PubMed ID: 25132654
[TBL] [Abstract][Full Text] [Related]
9. Expression of the receptor MPL and proliferative effects of its ligand thrombopoietin on human leukemia cells.
Quentmeier H; Zaborski M; Graf G; Ludwig WD; Drexler HG
Leukemia; 1996 Feb; 10(2):297-310. PubMed ID: 8637239
[TBL] [Abstract][Full Text] [Related]
10. Expression of thrombopoietin receptor and its functional role in human B-precursor leukemia cells with 11q23 translocation or Philadelphia chromosome.
Iijima K; Sugita K; Inukai T; Goi K; Tezuka T; Uno K; Sato H; Kagami K; Nakazawa S
Leukemia; 2000 Sep; 14(9):1598-605. PubMed ID: 10995006
[TBL] [Abstract][Full Text] [Related]
11. Establishment of a novel mesenchymal stem cell-based regimen for chronic myeloid leukemia differentiation therapy.
Zuo S; Sun L; Wang Y; Chen B; Wang J; Ge X; Lu Y; Yang N; Shen P
Cell Death Dis; 2021 Feb; 12(2):208. PubMed ID: 33627636
[TBL] [Abstract][Full Text] [Related]
12. Thrombopoietin: expression of its receptor MPL and proliferative effects on leukemic cells.
Drexler HG; Quentmeier H
Leukemia; 1996 Sep; 10(9):1405-21. PubMed ID: 8751457
[TBL] [Abstract][Full Text] [Related]
13. Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico Approach.
Lozano ML; Segú-Vergés C; Coma M; Álvarez-Roman MT; González-Porras JR; Gutiérrez L; Valcárcel D; Butta N
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34199099
[TBL] [Abstract][Full Text] [Related]
14. JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation.
Besancenot R; Roos-Weil D; Tonetti C; Abdelouahab H; Lacout C; Pasquier F; Willekens C; Rameau P; Lecluse Y; Micol JB; Constantinescu SN; Vainchenker W; Solary E; Giraudier S
Blood; 2014 Sep; 124(13):2104-15. PubMed ID: 25143485
[TBL] [Abstract][Full Text] [Related]
15. Use of human leukemia-lymphoma cell lines in hematological research: effects of thrombopoietin on human leukemia cell lines.
Drexler HG; Quentmeier H
Hum Cell; 1996 Dec; 9(4):309-16. PubMed ID: 9183663
[TBL] [Abstract][Full Text] [Related]
16. Impact of chicken thrombopoietin and its receptor c-Mpl on hematopoietic cell development.
Bartunek P; Karafiat V; Bartunkova J; Pajer P; Dvorakova M; Kralova J; Zenke M; Dvorak M
Exp Hematol; 2008 Apr; 36(4):495-505. PubMed ID: 18243490
[TBL] [Abstract][Full Text] [Related]
17. Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag.
Erickson-Miller CL; Kirchner J; Aivado M; May R; Payne P; Chadderton A
Leuk Res; 2010 Sep; 34(9):1224-31. PubMed ID: 20202683
[TBL] [Abstract][Full Text] [Related]
18. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.
Erickson-Miller CL; Delorme E; Tian SS; Hopson CB; Landis AJ; Valoret EI; Sellers TS; Rosen J; Miller SG; Luengo JI; Duffy KJ; Jenkins JM
Stem Cells; 2009 Feb; 27(2):424-30. PubMed ID: 19038790
[TBL] [Abstract][Full Text] [Related]
19. Thrombopoietin receptor agonists in primary immune thrombocytopenia.
Siegal D; Crowther M; Cuker A
Semin Hematol; 2013 Jan; 50 Suppl 1(0 1):S18-21. PubMed ID: 23664510
[TBL] [Abstract][Full Text] [Related]
20. Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists.
Gilreath J; Lo M; Bubalo J
Drugs; 2021 Jul; 81(11):1285-1305. PubMed ID: 34160821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
